SunTrust analyst James Sheehan attributes the 26% jump in shares of American Vanguard (AVD) over the last week to speculation that mosquitocide sales will surge in response to the Zika virus, but he believes the Zika opportunity is being overestimated. The analyst maintains his Neutral rating and $14 price target on American Vanguard shares.
Search
New Posts
5 Key Changes for Real Estate Agents in a Changing Market: What You Need to Know
UK Clears Microsoft’s Partnership with Inflection AI: A New Era in AI Collaboration
Pets Drive Homebuying, Renovation Decisions
No Link Between Mobile Phones and Brain Cancer, WHO-Backed Study Says
How Barbie is Giving Fresh Energy to Its Tagline and Catching WNBA Fever
Leave A Comment